Content Tagged clopidogrel Subscribe to RSS Feed

Clopidogrel in CYP2C19 poor metabolizers: Four-fold dose increase may be needed

Published: Aug 31st, 2014

Clopidogrel is an antiplatelet agent that is bioactivated through a two-step process involving the polymorphic CYP2C19 enzyme. CYP2C19 genotype can be used to predict clopidogrel response, particularly in patients undergoing […]

UF Health Clinical Services & Patient Resources

Published: Aug 8th, 2014

The UF Health Personalized Medicine Program partners with health professionals and patients at UF Health and across the state to develop, implement, study and refine methods that allow genetic information […]

Genetic Testing for Clopidogrel

Published: Aug 1st, 2014

Interventional cardiologists at UF Health order a CYP2C19 genetic test through the UF Health Personalized Medicine Program and UF Health Pathology Laboratories to help determine the right medicine and the […]

CYP2C19 genotype variability: Effects on voriconazole and metabolite levels

Published: Jun 15th, 2014

Teresa Vo, PharmD, 2013-2014 PGY2 Resident in Personalized Medicine In a prospective evaluation of 95 patients treated with voriconazole (Vfend—Pfizer) over a 2-year period, CYP2C19 and CYP2C9 genotypes were not […]

Clopidogrel: CYP2C19, CYP1A2 effects in some post-MI patients

Published: Jun 1st, 2014

Daniel Zambrano (University of Florida College of Pharmacy PharmD Candidate, Class of 2015)   A recent large study showed associations between both loss-of-function and gain-of-function CYP polymorphisms and poor outcomes […]